Press Release – STELLA PHARMA CORPORATION

Press Release BNCT

November 14th, 2024

Announcement of Agreement Conclusion with TAE LIFE SCIENCES for Collaboration in the Development and Commercialization of BPA Drug for BNCT in Europe and the US

STELLA PHARMA CORPORATION announced today that our Company has entered into a D……

Press Release BNCT SPM-011

September 25th, 2024

Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma

Our product Borofalan (10B) (development code: SPM-011), which we are developin……

Press Release BNCT SPM-011

September 10th, 2024

Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma

Stella Pharma completed the enrollment of patients for the domestic phase II do……

Press Release BNCT Information

September 6th, 2024

Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT

Stella Pharma announces that it has signed an agreement with the National Cance……

Press Release SPM-011 Information

August 30th, 2024

Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma

Stella Pharma announces that it has applied to the Japanese Ministry of Health,……

Press Release BNCT

July 16th, 2024

Specified Clinical Research Contract concluded with Edogawa Hospital

― Providing our drug for Research on FDG-PET-positive shallow tumors ― Stell……

Press Release BNCT

June 24th, 2024

BNCT for Thoracic Malignant Tumor – Submission of Trial Plan Notification for Domestic Clinical Trial Phase I/II

We would like to announce that our company submitted the trial plan notificatio……

Press Release BNCT

May 9th, 2024

BNCT Project in Hong Kong-Shenzhen – Memorandum of Understanding signing ceremony

Together with China Biotech Services Holdings Limited (CBSH), our partner for t……

Press Release Steboronine® BNCT

April 16th, 2024

Paper published: Clinical trial about Boron Neutron Capture Therapy for recurrent breast cancer

Our company provides Steboronine® for the investigator-initiated specified clin……

Press Release BNCT

March 29th, 2024

Published in “Nature” – Article about our Company and BNCT

The international science journal “Nature” published in its special edition “Ra……

Press Release

March 14th, 2024

Observation period completed for primary endpoint – Phase II study in patients with recurrent high-grade meningioma

Our company provides the boron drug for BNCT (Boron Neutron Capture Therapy), w……

Press Release BNCT

March 4th, 2024

Interim Analysis Results of Post-Marketing Surveillance of Our Drug Product published ― Safety of Boron Neutron Capture Therapy with Borofalan(10B) and Its Efficacy on Recurrent Head and Neck Cancer

The results regarding safety and effectiveness of our product Borofalan(10B), u……